SCHEMBL6137213

SCHEMBL6137213

CCOC(=O)c1c(C)nc(C)c(C#N)c1-c1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.54
L3MBTL1 Q9Y468 2/20 0.54
HTT P42858 2/20 0.51
GAA P10253 3/20 0.51
LMNA P02545 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
KDM4E B2RXH2 3/20 0.50
HPGD P15428 3/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
POLB P06746 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 3/20 0.49
ALOX5 P09917 3/20 0.44
SLC6A2 P23975 1/20 0.44
SLC6A4 P31645 1/20 0.44
SLC6A3 Q01959 1/20 0.44
MEN1 O00255 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6137355 0.86 ALDH1A1 (0.56) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL28437809 0.83 GAA (0.61) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL6137231 0.82 ALDH1A1 (0.60) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL6137171 0.80 ALDH1A1 (0.58) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL26664883 0.80 ALDH1A1 (0.55) ALDH1A1L3MBTL1HTTLMNASMN1; SMN2
SCHEMBL4755334 0.80 MAPK14 (0.48) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL6137173 0.79 AR (0.57) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL6137339 0.78 ALDH1A1 (0.56) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL8917192 0.78 ALDH1A1 (0.65) ALDH1A1L3MBTL1HTTGAALMNA
SCHEMBL6137255 0.78 SMN1; SMN2 (0.56) ALDH1A1L3MBTL1HTTGAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1372657-A4 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2005-11-09 EP disclosed
EP-1372657-A2 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS Bristol-Myers Squibb Company (US) 2004-01-02 EP disclosed
WO-2002078639-A2 A METHOD OF TREATING PROLIFERATIVE DISEASES USING EG5 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2002-10-10 WO disclosed